Breathtec BioMedical, Inc. plans to commence a clinical trial research review into NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion-Israel Institute of Technology that has been in-licensed by Breathtec.
The system was developed to detect the volatile biomarkers of diseases from exhaled breath. The company selected the Health & Technology District on Innovation Boulevard in Surrey, BC to hold its clinical trials for respiratory infections.
The nanotechnology-based NA-NOSE breath analysis system is used for screening of potentially life-threatening diseases.
The licensed technology will be clinically evaluated as a non-invasive point of care device for early detection of community and hospital based infections such as Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold.
